Scientific deep-dive

How to Taper Off Semaglutide and Tirzepatide Safely: The Discontinuation Protocol Guide

There is no FDA-approved taper for semaglutide or tirzepatide. In the STEP 1 extension, people who stopped semaglutide regained about 67% of lost weight within a year, and SURMOUNT-4 showed a similar pattern. Options: stay on maintenance, step down, or stop with a plan.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·5 citations

There is no FDA-approved tapering schedule for semaglutide or tirzepatide. The Wegovy and Zepbound prescribing information both treat discontinuation as “simply stop” [4, 5]. But the clinical reality is more complicated: in the STEP-4 trial [1], patients switched to placebo at week 20 regained 6.9% of body weight over the next 48 weeks, the STEP-1 extension [2] found that people who stopped semaglutide regained about two-thirds of their lost weight within a year, and the SURMOUNT-4 trial [3] showed a similar rebound pattern for tirzepatide. This is not a failure of willpower — it's a documented physiological rebound driven by the same appetite and energy-expenditure mechanisms the drug was suppressing. This guide walks through the evidence-based options: continuing at maintenance (the trial-supported protocol), stepping down to a lower dose (off-label but increasingly used), or full discontinuation with a lifestyle bridge plan. Any actual tapering or discontinuation decision belongs with your prescriber.

What STEP-4 and SURMOUNT-4 actually showed

STEP-4 (Rubino et al., JAMA 2021 [1]) was the landmark maintenance trial for semaglutide. The design:

  • All participants started on semaglutide 2.4 mg and completed the standard 20-week titration ramp
  • At week 20, participants were randomized to either continue semaglutide 2.4 mg for an additional 48 weeks, or switch to placebo
  • The primary endpoint was percent change in body weight from week 20 to week 68

The results [1]:

ArmWeight change from wk 20 to wk 68
Continued semaglutide 2.4 mg−7.9% (additional loss beyond week 20)
Switched to placebo (discontinued)+6.9% (regain)

The between-group difference was approximately 14.8 percentage points [1]. On the regain side, patients in the placebo arm had lost a mean 10.6% during the 20-week run-in and then gained 6.9% over the following 48 weeks, reversing much, but not all, of that loss. The STEP-1 extension data (Wilding et al., DOM 2022 [2]) followed STEP-1 patients for a year after stopping and showed that they regained 11.6 of the 17.3 percentage points they had lost, about two-thirds.

SURMOUNT-4 (Aronne et al., JAMA 2024 [3]) replicated this pattern for tirzepatide. Patients who completed the 36-week titration + early-maintenance phase and then switched to placebo regained approximately 14 percentage points of body weight, while patients who continued tirzepatide lost an additional 5.5 percentage points. The conclusion from both trials is consistent: GLP-1 therapy works for as long as you take it, and the weight comes back when you stop.

Magnitude comparison

STEP-4 and SURMOUNT-4 randomized continue-vs-stop magnitudes — continuing on the maintenance dose produced additional loss, while switching to placebo reversed most of the prior loss within 1 year.[1][3]

  • Continue Wegovy 2.4 mg (STEP-4)7.9 % added TBWL
    Wk 20 → Wk 68
  • Stop Wegovy → placebo (STEP-4)6.9 % regained
    Wk 20 → Wk 68
  • Continue Zepbound 10 or 15 mg (SURMOUNT-4)5.5 % added TBWL
    Wk 36 → Wk 88
  • Stop Zepbound → placebo (SURMOUNT-4)14.0 % regained
    Wk 36 → Wk 88
STEP-4 and SURMOUNT-4 randomized continue-vs-stop magnitudes — continuing on the maintenance dose produced additional loss, while switching to placebo reversed most of the prior loss within 1 year.

Why weight rebounds after stopping

Three overlapping physiological mechanisms drive the rebound [1, 2, 3]:

  1. Appetite returns to baseline within weeks. Semaglutide has a half-life of about 1 week and tirzepatide about 5 days. The Wegovy label says semaglutide stays in circulation for about 5 to 7 weeks after the last dose; tirzepatide clears somewhat faster. As levels fall, the appetite-suppression effect goes with them, and many patients report “normal hunger” returning in the weeks after stopping.
  2. Resting metabolic rate adapted during weight loss. Rapid weight loss from any cause produces adaptive metabolic compensation — the body burns fewer calories at rest after losing weight than before. This effect is well-documented across diet, surgery, and drug interventions. When appetite returns to pre-therapy levels but metabolic rate stays suppressed, the caloric balance tips toward regain.
  3. Hormonal set-point pressure. Ghrelin, leptin, and other appetite hormones shift toward “defend the higher weight” after loss. GLP-1 therapy masks this pressure while it's active; stopping unmasks it. The set-point biology is the same in all successful weight-loss interventions and is the main reason “just eat less” doesn't work long-term for most patients.

The bottom line: rebound after GLP-1 discontinuation is biological, not behavioral. Patients who rebound are not failing — their physiology is doing exactly what the trial data predicts.

Option 1: Continue at maintenance dose (the trial-supported protocol)

This is the only protocol with direct trial evidence. The STEP-4 and SURMOUNT-4 continuation arms show that patients who stay on the maintenance dose continue to lose weight slowly and maintain the loss indefinitely [1, 3]. Both the Wegovy and Zepbound labels position the drugs as chronic weight management, meaning long-term use — not a course of treatment with a defined end.

Practical considerations for continuing indefinitely:

  • Continued cost — whether brand-name insurance coverage, compounded vial pricing, or the new Foundayo self-pay option (from $149/month at the lowest dose) option
  • Ongoing GI side-effect management — most patients tolerate maintenance dose long-term with minimal residual nausea
  • Long-term safety monitoring — annual review of gallbladder, thyroid, pancreatitis risk factors
  • Lean-mass preservation — protein targets and resistance training matter more during long-term use, not less

If you are on GLP-1 therapy and achieving your weight loss goals with tolerable side effects, the trial-supported answer is: don't stop. This is the position of both the Wegovy and Zepbound FDA labels [4, 5] and of most obesity-medicine specialists.

Option 2: Step down to a lower dose (off-label, unstudied)

An increasingly common off-label practice: instead of stopping entirely, patients step their dose down from maintenance to a lower level (e.g. from 2.4 mg semaglutide to 1 mg, or from 15 mg tirzepatide to 7.5 mg) in the hope of maintaining most of the weight loss at lower cost and lower side-effect burden.

There is no published trial evidence for this protocol. The STEP-4 and SURMOUNT-4 trials did not include a step-down arm. Anecdotally, some patients do maintain their weight at lower doses for months to years, while others experience gradual regain. The dose-response data from STEP-1 suggests lower doses produce lower appetite-suppression effect, which implies some rebound is likely, but the specific maintenance-at-lower-dose experience is an evidence vacuum.

Why patients try it anyway:

  • Cost reduction. A lower dose means the vial lasts longer, which directly reduces monthly expense.
  • Side effect tolerance. Patients who had significant GI symptoms at maintenance often tolerate lower doses better.
  • Perceived long-term safety. Less drug = perceived less risk, though the trial safety data does not directly support this intuition.

If you and your prescriber decide to try a step-down approach, the practical pattern most clinicians use:

  1. Drop one dose level (for example, 2.4 mg semaglutide → 1.7 mg). Stay at that dose for 4-8 weeks.
  2. Monitor weight closely — weekly weigh-ins rather than monthly.
  3. If weight is stable at the new dose for 8+ weeks, consider staying there. If weight is creeping up, either return to the previous dose or accept the slow regain.
  4. Re-evaluate every 3 months with your prescriber.

For more on the specific evidence (and evidence vacuum) around sub-therapeutic dosing, see our microdosing evidence guide.

Option 3: Full discontinuation with a lifestyle bridge

If you're going to stop entirely, the STEP-4 data [1] is unambiguous: expect rebound. The question is how to minimize it. The trial data does not support any specific lifestyle intervention that fully prevents rebound, but general weight-loss maintenance literature suggests the following improve odds of maintaining more of the loss:

  1. Don't stop at a dose above your long-term target weight. If you stop while still losing, you will regain to somewhere above your nadir. Plan the stop for after you have reached a weight you are willing to return to.
  2. Stabilize for 4-8 weeks at the target weight on the drug before stopping. This gives your body time to adapt to the lower weight before the drug is removed.
  3. Have a caloric target in place before you stop. The appetite suppression is about to return to baseline. A sustainable 500-750 kcal/day caloric deficit plan, pre-calculated, with specific meal templates, is the single most-studied maintenance intervention.
  4. Maintain resistance training and high protein. Both improve post-discontinuation outcomes by preserving lean mass and improving metabolic rate. See our muscle mass deep-dive and our diet guide.
  5. Weigh yourself daily. Early detection of regain is critical. If you're up 5 lbs from nadir within 4 weeks of stopping, talk to your prescriber about resuming therapy before the rebound compounds.
  6. Know the resumption option. Stopping is not one-way. If the rebound proves intolerable, you can restart semaglutide or tirzepatide — compare the best semaglutide providers if you need a new prescriber. The re-titration takes the standard 16-20 weeks and you should expect to lose the regained weight over a similar timeline.

Medical reasons to actually stop

A subset of patients have clinical reasons to discontinue that override the rebound concern:

  • Pregnancy or trying to conceive. The Wegovy label recommends discontinuing at least 2 months before a planned pregnancy [4]; the Zepbound label sets no pre-conception window and says to discontinue once pregnancy is recognized [5]. Pregnancy is not a listed contraindication, but both labels warn of possible fetal harm, so the drugs are not used during pregnancy.
  • Pancreatitis. Acute pancreatitis is a Section 5 Warning and Precaution on the GLP-1 labels — not a boxed warning. (The only boxed warning on Wegovy, Ozempic, Zepbound, and Mounjaro is for thyroid C-cell tumors / medullary thyroid carcinoma [4, 5].) Confirmed acute pancreatitis is a hard stop — do not resume.
  • Gallbladder surgery. The drugs increase gallbladder-disease risk and are typically held perioperatively.
  • Severe diabetic retinopathy progression in T2D patients on Ozempic. The semaglutide-class retinopathy signal originates in SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186) and is in the Ozempic label Section 5.3. The Mounjaro (tirzepatide) label now carries a similar warning for patients with a history of diabetic retinopathy (Section 5.7).
  • Gastroparesis or severe reflux that does not resolve with dose reduction.
  • Scheduled surgery or deep sedation. The GLP-1 labels recommend holding the drug before procedures with anesthesia because of aspiration risk from delayed gastric emptying.

In these cases, the discontinuation is clinically driven and the rebound concern is secondary. Your prescriber will manage the transition.

The decision framework

A practical framework for the stop-or-continue decision:

  1. Is there a medical reason to stop? If yes, stop under prescriber supervision and manage the rebound downstream. This is a non-negotiable clinical decision.
  2. Are you at a stable goal weight with tolerable side effects? If yes, the trial-supported answer is to continue at maintenance dose indefinitely [1, 3].
  3. Is cost the primary obstacle? Before stopping, explore lower-cost options: compounded vials, Foundayo self-pay (from $149/month at the lowest dose), or the manufacturers’ self-pay prices. See our pricing index.
  4. Are side effects the primary obstacle? Try a dose step-down first (Option 2), or switch to a different GLP-1 (see our switching guide) before discontinuing entirely.
  5. Have you truly decided you want to stop? Then plan the full-discontinuation protocol with your prescriber at least 1-2 months in advance of the stop date. Do not stop cold on a whim.

What to call your prescriber about

Before stopping, call your prescriber if:

  • You're considering discontinuation for any reason — the conversation should happen before the last dose, not after
  • You're experiencing side effects you can't tolerate (there may be management options short of stopping)
  • Cost has become prohibitive (there are often prescriber-side options to reduce cost)
  • You're pregnant or planning pregnancy
  • You're scheduled for surgery within the next 4 weeks
  • You've already stopped and are experiencing rapid rebound — resuming sooner is easier than later

Related research and tools

For the full STEP-4 deep-dive on what happens after discontinuation, see our post-discontinuation guide. For switching to a different GLP-1 instead of stopping, see our switching guide. For step-down dosing considerations, see our microdosing evidence guide. For the expected weight trajectory on each drug, use our weight loss calculator. For the lean-mass preservation protocol, see our muscle mass deep-dive.

References

  1. 1.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
  2. 2.Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. PMID: 35441470.
  3. 3.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
  4. 4.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information. DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  5. 5.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Frequently Asked Questions

You can — semaglutide and tirzepatide are not physically addictive and there is no withdrawal syndrome — but the trials showed substantial weight regain (about two-thirds of lost weight within a year after stopping semaglutide in the STEP 1 extension, and about half on tirzepatide in SURMOUNT-4) when GLP-1 therapy was stopped abruptly. No published trial has tested whether a gradual taper preserves more weight; if you decide to stop, do it with your prescriber and a lifestyle plan.
There is no FDA-approved tapering protocol because the trials studied continuous use. Many clinicians step down through the lower dose levels in 4-8 week increments (e.g., Wegovy 2.4mg → 1.7mg → 1.0mg → 0.5mg → 0.25mg, then stop), monitoring weight, hunger, and metabolic markers at each step. The slower the taper, the more time you have to stabilize behaviors at each rung.
In the STEP 1 extension trial, semaglutide patients regained about two-thirds of their lost weight within 12 months of stopping. SURMOUNT-4 showed about half of lost weight regained within a year of stopping tirzepatide. Individual results vary widely based on lifestyle behaviors, baseline metabolism, and how long you were on the drug. Regain is not inevitable but it is the statistical norm.
Yes, in most patients. The appetite suppression and 'food noise' reduction effects are pharmacologic — they depend on the drug being in your system. In the weeks after the last dose, as drug levels fall, hunger and food preoccupation typically return toward pre-treatment levels. This is the central reason most clinicians now think of GLP-1 therapy as long-term rather than time-limited.
Some clinicians use a lower 'maintenance' dose (e.g., Wegovy 1.0mg or Zepbound 5mg) to preserve weight loss without the cost or side-effect burden of the full dose. There are no head-to-head trials proving this approach works long-term, but observationally it's common practice. Discuss the maintenance vs. taper-and-stop tradeoff with your prescriber.

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $129/mo (“starting at” price)

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo (sale price)

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $179/mo (prepaid plan rate)

Get started →